Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C-albicans in human immunodeficiency virus-infected patients

被引:76
作者
Martins, MD [1 ]
Lozano-Chiu, M [1 ]
Rex, JH [1 ]
机构
[1] Univ Texas, Sch Med, Dept Internal Med,Div Infect Dis, Ctr Study Emerging & Reemerging Pathogens, Houston, TX USA
关键词
D O I
10.1086/515006
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In order to determine the current prevalence and incidence of fluconazole-resistant oropharyngeal candidiasis among human immunodeficiency virus (HIV)-infected patients, we conducted a prospective observational study of a consecutive series of HPV-infected patients. Of 128 enrolled patients, 70 patients completed four quarterly follow-up visits over a period of 1 year. Over this period, declining rates of carriage of Candida albicans (from 61% to 39%; P = .008) and of oropharyngeal candidiasis (from 30% to 4%; P < .001) were documented. Il:rends toward reduction in the frequency of fluconazole-resistant isolates (MIC, greater than or equal to 64 mu g/mL) were also seen. During the survey period, the mean (median) number of antiretroviral agents used per patient rose from 0.5 (0) to 1.8 (2) (P < .001). Thus, rather than progression, we observed declining rates of oropharyngeal candidiasis, C. albicans carriage, and fluconazole-resistant C. albicans in a cohort of HIV-infected patients treated with increasingly effective antiretroviral therapy.
引用
收藏
页码:1291 / 1294
页数:4
相关论文
共 24 条
[1]  
Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1
[2]   Protease inhibitors for HIV infection [J].
Bartlett, JG .
ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) :1086-1088
[3]   Reversible fluconazole resistance in Candida albicans: A potential in vitro model [J].
Calvet, HM ;
Yeaman, MR ;
Filler, SG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :535-539
[4]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969
[5]   Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor [J].
Carr, A ;
Cooper, DA .
LANCET, 1997, 349 (9057) :995-996
[6]   Candidiasis: The emergence of a novel species, Candida dubliniensis [J].
Coleman, DC ;
Sullivan, DJ ;
Bennett, DE ;
Moran, GP ;
Barry, HJ ;
Shanley, DB .
AIDS, 1997, 11 (05) :557-567
[7]   HIV-1 protease inhibitors - A review for clinicians [J].
Deeks, SG ;
Smith, M ;
Holodniy, M ;
Kahn, JO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (02) :145-153
[8]   CAN WE PREVENT AZOLE RESISTANCE IN FUNGI [J].
DENNING, DW .
LANCET, 1995, 346 (8973) :454-455
[9]   2-5 year remission of AIDS-associated progressive multifocal leukoencephalopathy with combined antiretroviral therapy [J].
Elliot, B ;
Aromin, I ;
Gold, R ;
Flanigan, T ;
Mileno, M .
LANCET, 1997, 349 (9055) :850-850
[10]  
Gazzard B, 1996, AIDS, V10, pS3